Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with apatinib for TP53-mutant non-small cell lung cancer
ChiCTR2000031978Phase 4Not yet recruiting
- Sponsor
- Nanjing Chest Hospital
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Chest Hospital. Primary endpoint: Progression-free survival. Planned start May 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000031978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031978.